All In Biotech

Drug Trial Radar · NCT01134055

Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration

MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration

Last checked: Nov 20, 2026Latest source record: Jan 8, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 510 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

510

Actual

Start

Jun 1, 2010

Primary completion

Oct 1, 2012

Study completion Oct 1, 2012

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
May 31, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety and efficacy of different dosage regimens of pazopanib eye drops for the treatment of neovascular age-related macular degeneration.

Conditions

  • Macular Degeneration

Interventions

  • pazopanib eye dropsDrug

    A tyrosine kinase inhibitor of multiple receptors including vascular endothelial growth factor receptors and platelet-derived growth factor receptors.

  • placeboDrug

    placebo eye drops

  • ranibizumab intravitreal injectionBiological

    Humanized recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Best-corrected Visual Acuity (BCVA) as Measured by the Number of Letters Read on the Early Treatment of Diabetic Retinopathy Study (ETDRS) Grading Charts at a Starting Distance of 4 Meters at Week 52Time frame: Day 1 and 52 weeks

Locations

77 sites in 9 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Peoria, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Irvine, California

  • GSK Investigational Site

    Loma Linda, California

  • GSK Investigational Site

    Poway, California

  • GSK Investigational Site

    Santa Ana, California

  • GSK Investigational Site

    Golden, Colorado

  • GSK Investigational Site

    Fort Myers, Florida

  • GSK Investigational Site

    Winter Haven, Florida

  • GSK Investigational Site

    Chicago, Illinois

  • GSK Investigational Site

    Leawood, Kansas

  • GSK Investigational Site

    Paducah, Kentucky

  • GSK Investigational Site

    Baltimore, Maryland

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    Royal Oak, Michigan

  • GSK Investigational Site

    Traverse City, Michigan

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    Asheville, North Carolina

  • GSK Investigational Site

    Chapel Hill, North Carolina

  • GSK Investigational Site

    Charlotte, North Carolina

  • GSK Investigational Site

    Beachwood, Ohio

  • GSK Investigational Site

    Cleveland, Ohio

  • GSK Investigational Site

    Cleveland, Ohio

  • GSK Investigational Site

    Columbus, Ohio

  • GSK Investigational Site

    Ashland, Oregon

  • GSK Investigational Site

    Portland, Oregon

  • GSK Investigational Site

    Philadelphia, Pennsylvania

  • GSK Investigational Site

    Austin, Texas

  • GSK Investigational Site

    Dallas, Texas

  • GSK Investigational Site

    Fort Worth, Texas

  • GSK Investigational Site

    Salt Lake City, Utah

  • GSK Investigational Site

    Seattle, Washington

  • GSK Investigational Site

    Silverdale, Washington

  • GSK Investigational Site

    Madison, Wisconsin

  • GSK Investigational Site

    Sydney, New South Wales, Australia

  • GSK Investigational Site

    Sydney, New South Wales, Australia

  • GSK Investigational Site

    Melbourne, Victoria, Australia

Showing 40 of 77 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.